

# Marius M Hoeper

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1957774/publications.pdf>

Version: 2024-02-01

225  
papers

34,160  
citations

10956

71  
h-index

3638

180  
g-index

229  
all docs

229  
docs citations

229  
times ranked

18560  
citing authors

#	ARTICLE	IF	CITATIONS
1	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. <i>European Heart Journal</i> , 2016, 37, 67-119.	1.0	5,074
2	Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). <i>European Heart Journal</i> , 2009, 30, 2493-2537.	1.0	3,108
3	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. <i>European Respiratory Journal</i> , 2015, 46, 903-975.	3.1	2,415
4	Definitions and Diagnosis of Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D42-D50.	1.2	1,467
5	Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. <i>New England Journal of Medicine</i> , 2013, 369, 319-329.	13.9	1,144
6	Diagnosis and Assessment of Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S55-S66.	1.2	984
7	Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2015, 373, 834-844.	13.9	906
8	Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 2243-2278.	1.0	903
9	Chronic Thromboembolic Pulmonary Hypertension (CTEPH). <i>Circulation</i> , 2011, 124, 1973-1981.	1.6	860
10	Chronic Thromboembolic Pulmonary Hypertension. <i>Circulation</i> , 2006, 113, 2011-2020.	1.6	791
11	Selexipag for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2015, 373, 2522-2533.	13.9	790
12	Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension. <i>Circulation</i> , 2006, 114, 1482-1489.	1.6	606
13	Extracorporeal Membrane Oxygenation in Awake Patients as Bridge to Lung Transplantation. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 763-768.	2.5	539
14	A global view of pulmonary hypertension. <i>Lancet Respiratory Medicine</i> , 2016, 4, 306-322.	5.2	523
15	Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2008, 52, 2127-2134.	1.2	506
16	Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension. <i>Circulation</i> , 2016, 133, 859-871.	1.6	506
17	Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2546-2552.	1.2	498
18	Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. <i>European Respiratory Journal</i> , 2017, 50, 1700740.	3.1	489

#	ARTICLE	IF	CITATIONS
19	Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 127, 1128-1138.	1.6	482
20	Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S78-S84.	1.2	463
21	Portopulmonary hypertension and hepatopulmonary syndrome. <i>Lancet, The</i> , 2004, 363, 1461-1468.	6.3	440
22	Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry. <i>International Journal of Cardiology</i> , 2013, 168, 871-880.	0.8	357
23	A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2000, 35, 176-182.	1.2	296
24	ERS statement on chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2021, 57, 2002828.	3.1	287
25	Intensive Care Unit Management of Patients with Severe Pulmonary Hypertension and Right Heart Failure. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 1114-1124.	2.5	259
26	Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). <i>European Respiratory Journal</i> , 2015, 45, 1293-1302.	3.1	247
27	Pre-Capillary, Combined, and Post-Capillary Pulmonary Hypertension. <i>Journal of the American College of Cardiology</i> , 2016, 68, 368-378.	1.2	244
28	Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. <i>American Heart Journal</i> , 2007, 153, 127-132.	1.2	243
29	Sotatercept for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2021, 384, 1204-1215.	13.9	224
30	Cannulation strategies for percutaneous extracorporeal membrane oxygenation in adults. <i>Clinical Research in Cardiology</i> , 2016, 105, 283-296.	1.5	197
31	Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2015, 46, 405-413.	3.1	184
32	Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. <i>European Respiratory Journal</i> , 2017, 49, 1602409.	3.1	178
33	COVID-19 immune signatures reveal stable antiviral T <sub>H</sub> 1 cell function despite declining humoral responses. <i>Immunity</i> , 2021, 54, 340-354.e6.	6.6	177
34	Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension. <i>Chest</i> , 2005, 128, 2363-2367.	0.4	166
35	An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan. <i>European Respiratory Review</i> , 2017, 26, 160121.	3.0	156
36	Atrial flutter and fibrillation in patients with pulmonary hypertension. <i>International Journal of Cardiology</i> , 2013, 167, 2300-2305.	0.8	153

#	ARTICLE	IF	CITATIONS
37	Outcome after Cardiopulmonary Resuscitation in Patients with Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 341-344.	2.5	152
38	End points and clinical trial designs in pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2004, 43, S48-S55.	1.2	147
39	Chronic thromboembolic pulmonary hypertension. <i>Lancet Respiratory Medicine</i> , 2014, 2, 573-582.	5.2	146
40	Plexiform Lesions in Pulmonary Arterial Hypertension. <i>American Journal of Pathology</i> , 2011, 179, 167-179.	1.9	144
41	Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801906.	3.1	144
42	Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018. <i>International Journal of Cardiology</i> , 2018, 272, 69-78.	0.8	140
43	Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 780-790.	5.2	139
44	Systemic Consequences of Pulmonary Hypertension and Right-Sided Heart Failure. <i>Circulation</i> , 2020, 141, 678-693.	1.6	139
45	Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. <i>European Respiratory Journal</i> , 2013, 41, 1302-1307.	3.1	131
46	Chronic thromboembolic pulmonary hypertension: Evaluation with 64-detector row CT versus digital subtraction angiography. <i>European Journal of Radiology</i> , 2009, 71, 49-54.	1.2	130
47	Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. <i>European Respiratory Journal</i> , 2013, 41, 853-860.	3.1	130
48	Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 372-380.	5.2	130
49	New Treatments for Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 1209-1216.	2.5	129
50	COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2022, 60, 2102311.	3.1	124
51	The changing landscape of pulmonary arterial hypertension and implications for patient care. <i>European Respiratory Review</i> , 2014, 23, 450-457.	3.0	122
52	Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 594-604.	5.2	119
53	RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. <i>European Respiratory Journal</i> , 2017, 50, 1602425.	3.1	113
54	Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. <i>Critical Care</i> , 2018, 22, 285.	2.5	113

#	ARTICLE	IF	CITATIONS
55	Reappearance of effector T cells is associated with recovery from COVID-19. <i>EBioMedicine</i> , 2020, 57, 102885.	2.7	109
56	Circulating cardiovascular <scp>microRNAs</scp> in critically ill <scp>COVID</scp> patients. <i>European Journal of Heart Failure</i> , 2021, 23, 468-475.	2.9	107
57	Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 1435-1444.	0.3	104
58	Current and future treatments of pulmonary arterial hypertension. <i>British Journal of Pharmacology</i> , 2021, 178, 6-30.	2.7	104
59	Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. <i>Cellular and Molecular Immunology</i> , 2021, 18, 936-944.	4.8	98
60	Indications for and Outcomes After Combined Lung and Liver Transplantation: A Single-Center Experience on 13 Consecutive Cases. <i>Transplantation</i> , 2008, 85, 524-531.	0.5	96
61	Diffusion Capacity and Mortality in Patients With Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2016, 4, 441-449.	1.9	95
62	Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations of the Cologne Consensus Conference 2011. <i>International Journal of Cardiology</i> , 2011, 154, S54-S60.	0.8	93
63	Pulmonary Hypertension. <i>Deutsches Arzteblatt International</i> , 2017, 114, 73-84.	0.6	87
64	Extracorporeal membrane oxygenation instead of invasive mechanical ventilation in patients with acute respiratory distress syndrome. <i>Intensive Care Medicine</i> , 2013, 39, 2056-2057.	3.9	85
65	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 573-584.	5.2	85
66	Extracorporeal Membrane Oxygenation Watershed. <i>Circulation</i> , 2014, 130, 864-865.	1.6	83
67	Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. <i>European Heart Journal</i> , 2017, 38, ehw597.	1.0	83
68	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. <i>Journal of the American College of Cardiology</i> , 2018, 71, 752-763.	1.2	82
69	Clinical course, treatment and outcome of <i>Pneumocystis pneumonia</i> in immunocompromised adults: a retrospective analysis over 17 years. <i>Critical Care</i> , 2018, 22, 307.	2.5	81
70	Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias. <i>PLoS ONE</i> , 2015, 10, e0141911.	1.1	80
71	Incidence and characteristics of chronic thromboembolic pulmonary hypertension in Germany. <i>Clinical Research in Cardiology</i> , 2018, 107, 548-553.	1.5	77
72	C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19. <i>Infection</i> , 2021, 49, 935-943.	2.3	76

#	ARTICLE	IF	CITATIONS
73	Osteopontin in Patients With Idiopathic Pulmonary Hypertension. <i>Chest</i> , 2011, 139, 1010-1017.	0.4	75
74	Definition, Classification, and Epidemiology of Pulmonary Arterial Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009, 30, 369-375.	0.8	72
75	Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. <i>European Heart Journal</i> , 2022, 43, 3387-3398.	1.0	69
76	Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1802004.	3.1	68
77	Risk assessment in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2018, 51, 1702606.	3.1	67
78	Veno-veno-arterial extracorporeal membrane oxygenation for respiratory failure with severe haemodynamic impairment: technique and early outcomes. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2015, 20, 761-767.	0.5	66
79	Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trial. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 1286-1295.	0.3	62
80	Pulmonary hypertension due to chronic lung disease: Updated Recommendations of the Cologne Consensus Conference 2011. <i>International Journal of Cardiology</i> , 2011, 154, S45-S53.	0.8	61
81	Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients. <i>European Respiratory Journal</i> , 2018, 52, 1800248.	3.1	61
82	Incidence and prevalence of pulmonary arterial hypertension in Germany. <i>International Journal of Cardiology</i> , 2016, 203, 612-613.	0.8	60
83	Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. <i>Lancet Respiratory Medicine</i> , 2016, 4, 894-901.	5.2	59
84	Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. <i>European Respiratory Journal</i> , 2022, 59, 2102024.	3.1	57
85	Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. <i>Lancet Respiratory Medicine</i> , 2022, 10, 937-948.	5.2	57
86	Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. <i>International Journal of Cardiology</i> , 2018, 272, 37-45.	0.8	56
87	The revised definition of pulmonary hypertension: exploring the impact on patient management. <i>European Heart Journal Supplements</i> , 2019, 21, K4-K8.	0.0	55
88	Pulmonary Hypertension in Patients With COPD. <i>Chest</i> , 2021, 160, 678-689.	0.4	55
89	MR Imaging-derived Regional Pulmonary Parenchymal Perfusion and Cardiac Function for Monitoring Patients with Chronic Thromboembolic Pulmonary Hypertension before and after Pulmonary Endarterectomy. <i>Radiology</i> , 2016, 279, 925-934.	3.6	54
90	Mid-term results of bilateral lung transplant with postoperatively extended intraoperative extracorporeal membrane oxygenation for severe pulmonary hypertension. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 163-170.	0.6	48

#	ARTICLE	IF	CITATIONS
91	Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry. <i>European Respiratory Journal</i> , 2021, 58, 2101483.	3.1	48
92	Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. <i>International Journal of Cardiology</i> , 2014, 172, 332-339.	0.8	47
93	Drug Treatment of Pulmonary Arterial Hypertension. <i>Drugs</i> , 2005, 65, 1337-1354.	4.9	46
94	Improved short- and long-term outcome of allogeneic stem cell recipients admitted to the intensive care unit: a retrospective longitudinal analysis of 942 patients. <i>Intensive Care Medicine</i> , 2018, 44, 1483-1492.	3.9	46
95	The new haemodynamic definition of pulmonary hypertension: evidence prevails, finally!. <i>European Respiratory Journal</i> , 2019, 53, 1900038.	3.1	44
96	Imaging of Pulmonary Hypertension in Adults: A Position Paper from the Fleischner Society. <i>Radiology</i> , 2021, 298, 531-549.	3.6	43
97	Therapeutic plasma exchange in acute liver failure. <i>Journal of Clinical Apheresis</i> , 2019, 34, 589-597.	0.7	42
98	Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society. <i>European Respiratory Journal</i> , 2021, 57, 2004455.	3.1	42
99	Update in Pulmonary Hypertension 2005. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 499-505.	2.5	40
100	Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study). <i>Respiratory Research</i> , 2018, 19, 258.	1.4	39
101	Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 300-309.	0.3	39
102	Performance of perfusion-weighted Fourier decomposition MRI for detection of chronic pulmonary emboli. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 72-79.	1.9	38
103	First identification of <i>rs113139666</i> mutation in heritable pulmonary arterial hypertension. <i>Clinical Science</i> , 2017, 131, 689-698.	1.8	38
104	Risk stratification in pulmonary arterial hypertension using Bayesian analysis. <i>European Respiratory Journal</i> , 2020, 56, 2000008.	3.1	38
105	Comparison of C-arm Computed Tomography and Digital Subtraction Angiography in Patients with Chronic Thromboembolic Pulmonary Hypertension. <i>CardioVascular and Interventional Radiology</i> , 2016, 39, 53-63.	0.9	37
106	Balloon pulmonary angioplasty: applicability of C-Arm CT for procedure guidance. <i>European Radiology</i> , 2016, 26, 4064-4071.	2.3	36
107	Effect of therapeutic plasma exchange on endothelial activation and coagulation-related parameters in septic shock. <i>Critical Care</i> , 2020, 24, 71.	2.5	36
108	Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension: Updated recommendations from the Cologne Consensus Conference 2018. <i>International Journal of Cardiology</i> , 2018, 272, 46-52.	0.8	33



#	ARTICLE	IF	CITATIONS
109	Extracorporeal membrane oxygenation in a nonintubated patient with acute respiratory distress syndrome. <i>European Respiratory Journal</i> , 2012, 40, 1296-1298.	3.1	32
110	Evaluation of the incidence of rare diseases: difficulties and uncertainties, the example of chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2017, 49, 1602522.	3.1	32
111	Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study. <i>Respiratory Medicine</i> , 2017, 128, 50-56.	1.3	31
112	Prevalence of Mental Disorders and Impact on Quality of Life in Patients With Pulmonary Arterial Hypertension. <i>Frontiers in Psychiatry</i> , 2021, 12, 667602.	1.3	30
113	Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination. <i>Clinical Infectious Diseases</i> , 2021, 73, 2000-2008.	2.9	30
114	State of the Art: Bridging to lung transplantation using artificial organ support technologies. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1385-1398.	0.3	29
115	REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 836-843.	0.3	29
116	The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry. <i>Clinical Research in Cardiology</i> , 2018, 107, 460-470.	1.5	29
117	REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 513-519.	0.3	29
118	Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 748-756.	0.3	29
119	Pregnancy in pulmonary arterial hypertension: Midterm outcomes of mothers and offspring. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 229-233.	0.3	28
120	Long-term outcomes after intraoperative extracorporeal membrane oxygenation during lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 915-925.	0.3	28
121	Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 716-721.	0.3	28
122	Cardio-pulmonary MRI for detection of treatment response after a single BPA treatment session in CTEPH patients. <i>European Radiology</i> , 2019, 29, 1693-1702.	2.3	27
123	CXCL13 in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>Respiratory Research</i> , 2016, 17, 21.	1.4	26
124	Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1235-1244.	0.3	26
125	More on idiopathic pulmonary arterial hypertension with a low diffusing capacity. <i>European Respiratory Journal</i> , 2017, 50, 1700354.	3.1	25
126	Reduced Right Ventricular Output Reserve in Patients With Systemic Sclerosis and Mildly Elevated Pulmonary Artery Pressure. <i>Arthritis and Rheumatology</i> , 2019, 71, 805-816.	2.9	25



#	ARTICLE	IF	CITATIONS
127	Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome. <i>Journal of Critical Care</i> , 2020, 57, 124-129.	1.0	25
128	Chronic thromboembolic pulmonary hypertension: Evaluation of 2D-perfusion angiography in patients who undergo balloon pulmonary angioplasty. <i>European Radiology</i> , 2017, 27, 4264-4270.	2.3	24
129	Quantitation of Perfused Lung Volume Using Hybrid SPECT/CT Allows Refining the Assessment of Lung Perfusion and Estimating Disease Extent in Chronic Thromboembolic Pulmonary Hypertension. <i>Clinical Nuclear Medicine</i> , 2018, 43, e170-e177.	0.7	24
130	Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. <i>BMC Pulmonary Medicine</i> , 2017, 17, 216.	0.8	23
131	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2021, 178, 106220.	1.3	23
132	Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry: Table A1. <i>BMJ Open Respiratory Research</i> , 2014, 1, e000010.	1.2	22
133	Pulmonary Artery Imaging in Patients with Chronic Thromboembolic Pulmonary Hypertension: Comparison of Cone-Beam CT and 64-Row Multidetector CT. <i>Journal of Vascular and Interventional Radiology</i> , 2016, 27, 361-368.e2.	0.2	22
134	Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 509-519.	0.3	22
135	Is there a vanishing pulmonary capillary syndrome?. <i>Lancet Respiratory Medicine</i> , 2017, 5, 676-678.	5.2	22
136	C-Arm computed tomography (CACT)-guided balloon pulmonary angioplasty (BPA): Evaluation of patient safety and peri- and post-procedural complications. <i>European Radiology</i> , 2019, 29, 1276-1284.	2.3	22
137	Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension. <i>EClinicalMedicine</i> , 2021, 34, 100822.	3.2	22
138	Oral iron supplementation with ferric maltol in patients with pulmonary hypertension. <i>European Respiratory Journal</i> , 2020, 56, 2000616.	3.1	22
139	Extracorporeal membrane oxygenation and surgical embolectomy for high-risk pulmonary embolism. <i>European Respiratory Journal</i> , 2019, 53, 1801773.	3.1	21
140	Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension. <i>Chest</i> , 2021, 160, 277-286.	0.4	21
141	Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock: results from a randomized controlled trial. <i>Critical Care</i> , 2022, 26, 134.	2.5	21
142	Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 494-503.	0.3	20
143	Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension-related hospitalization in the AMBITION trial. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 194-202.	0.3	19
144	Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension. <i>Respiratory Research</i> , 2022, 23, 74.	1.4	18

#	ARTICLE	IF	CITATIONS
145	Chronic Thromboembolic Pulmonary Hypertension Perioperative Monitoring Using Phase-Resolved Functional Lung (PREFUL)-MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 610-619.	1.9	17
146	Immunoglobulin deficiency as an indicator of disease severity in patients with COVID-19. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L590-L599.	1.3	17
147	Successful use of extracorporeal membrane oxygenation during induction chemotherapy in a patient with mediastinal tumor mass of a T lymphoblastic lymphoma. <i>Annals of Hematology</i> , 2016, 95, 1719-1721.	0.8	16
148	Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension. <i>Respiratory Research</i> , 2019, 20, 208.	1.4	16
149	Comparison of MRI and VQ-SPECT as a Screening Test for Patients With Suspected CTEPH: CHANGE-MRI Study Design and Rationale. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 51.	1.1	16
150	Time-Dependent Molecular Motifs of Pulmonary Fibrogenesis in COVID-19. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1583.	1.8	16
151	Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. <i>Respiratory Medicine</i> , 2017, 122, S18-S22.	1.3	15
152	Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI <sub>2</sub> ) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 401-408.	0.3	15
153	Risk-stratified outcomes with initial combination therapy in pulmonary arterial hypertension: Application of the REVEAL risk score. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 1410-1417.	0.3	15
154	MRI-derived Regional Biventricular Function in Patients with Chronic Thromboembolic Pulmonary Hypertension Before and After Pulmonary Endarterectomy. <i>Academic Radiology</i> , 2018, 25, 1540-1547.	1.3	15
155	Extracorporeal Membrane Oxygenation for Severe ARDS Due to Immune Diffuse Alveolar Hemorrhage. <i>Chest</i> , 2020, 157, 744-747.	0.4	14
156	Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 348-355.	0.3	13
157	Residual Pulmonary Hypertension After Pulmonary Endarterectomy. <i>Circulation</i> , 2016, 133, 1731-1733.	1.6	13
158	Nonocclusive Mesenteric Ischemia and Interventional Local Vasodilatory Therapy: A Meta-Analysis and Systematic Review of the Literature. <i>Journal of Intensive Care Medicine</i> , 2020, 35, 128-139.	1.3	13
159	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. <i>Respiratory Medicine</i> , 2021, 177, 106241.	1.3	13
160	Effects of therapeutic plasma exchange on the endothelial glycocalyx in septic shock. <i>Intensive Care Medicine Experimental</i> , 2021, 9, 57.	0.9	13
161	Blood carbon dioxide tension and risk in pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2020, 318, 131-137.	0.8	12
162	Comparative Analysis of Gene Expression in Fibroblastic Foci in Patients with Idiopathic Pulmonary Fibrosis and Pulmonary Sarcoidosis. <i>Cells</i> , 2022, 11, 664.	1.8	12

#	ARTICLE	IF	CITATIONS
163	Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates. <i>Annals of Thoracic Medicine</i> , 2014, 9, 1.	0.7	11
164	Single- and multiple-dose pharmacokinetics of ethambutol and rifampicin in a tuberculosis patient with acute respiratory distress syndrome undergoing extended daily dialysis and ECMO treatment. <i>International Journal of Infectious Diseases</i> , 2016, 42, 1-3.	1.5	11
165	“Better be awake” a role for awake extracorporeal membrane oxygenation in acute respiratory distress syndrome due to <i>Pneumocystis pneumonia</i> . <i>Critical Care</i> , 2019, 23, 418.	2.5	11
166	Therapeutic plasma exchange in acute on chronic liver failure. <i>Journal of Clinical Apheresis</i> , 2020, 35, 316-327.	0.7	10
167	Chronic thromboembolic pulmonary hypertension at the crossroad. <i>European Respiratory Journal</i> , 2014, 43, 1230-1232.	3.1	9
168	Acute hemodynamic effects of adaptive servoventilation in patients with pre-capillary and post-capillary pulmonary hypertension. <i>Respiratory Research</i> , 2015, 16, 137.	1.4	9
169	Age, risk and outcomes in idiopathic pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2018, 51, 1800629.	3.1	9
170	Development of hepatopulmonary syndrome during combination therapy for portopulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801880.	3.1	9
171	Molecular Profiling of Vascular Remodeling in Chronic Pulmonary Disease. <i>American Journal of Pathology</i> , 2020, 190, 1382-1396.	1.9	9
172	Impact of SARS-CoV-2-Pandemic on Mental Disorders and Quality of Life in Patients With Pulmonary Arterial Hypertension. <i>Frontiers in Psychiatry</i> , 2021, 12, 668647.	1.3	9
173	Pharmacokinetics of Remdesivir and GS-441524 during PIRRT and Seraph 100 Therapy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1256-1257.	2.2	9
174	Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 1172-1180.	0.3	9
175	Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 971-981.	0.3	9
176	Effect of Therapeutic Plasma Exchange on Immunoglobulin Deficiency in Early and Severe Septic Shock. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 1491-1497.	1.3	8
177	Impact of unilateral diaphragm elevation on postoperative outcomes in bilateral lung transplantation – a retrospective single-center study. <i>Transplant International</i> , 2021, 34, 474-487.	0.8	8
178	Extracorporeal membrane oxygenation in non-intubated immunocompromised patients. <i>Critical Care</i> , 2021, 25, 164.	2.5	8
179	Predictors of response to intra-arterial vasodilatory therapy of non-occlusive mesenteric ischemia in patients with severe shock: results from a prospective observational study. <i>Critical Care</i> , 2022, 26, 92.	2.5	8
180	Extracorporeal membrane oxygenation for acute respiratory distress syndrome due to <i>Pneumocystis pneumonia</i> . <i>European Respiratory Journal</i> , 2019, 54, 1900410.	3.1	7

#	ARTICLE	IF	CITATIONS
181	Mechanical circulatory support in refractory cardiogenic shock due to influenza virus-related myocarditis. <i>European Respiratory Journal</i> , 2020, 56, 2000925.	3.1	7
182	Refined risk stratification in pulmonary arterial hypertension and timing of lung transplantation. <i>European Respiratory Journal</i> , 2022, 60, 2103087.	3.1	7
183	Prevalence of Mental Disorders in Patients With Chronic Thromboembolic Pulmonary Hypertension. <i>Frontiers in Psychiatry</i> , 2022, 13, 821466.	1.3	7
184	C-Arm Computed Tomography Adds Diagnostic Information in Patients with Chronic Thromboembolic Pulmonary Hypertension and a Positive V/Q SPECT. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2016, 189, 49-56.	0.7	6
185	The Value of C-Arm Computed Tomography in Addition to Conventional Digital Subtraction Angiography in the Diagnostic Work-up of Patients with Suspected Chronic Thromboembolic Pulmonary Hypertension: An Update of 300 Patients. <i>Academic Radiology</i> , 2022, 29, S1-S10.	1.3	6
186	Direct oral anticoagulants in chronic thromboembolic pulmonary hypertension. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 791-796.	1.0	6
187	Was Paul Wood wrong about pre-capillary pulmonary hypertension protecting against pulmonary congestion in left heart disease?. <i>European Heart Journal</i> , 2022, 43, 3432-3434.	1.0	6
188	Response to Letters Regarding Article, "Anticoagulation and Survival in Pulmonary Arterial Hypertension: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPETE)". <i>Circulation</i> , 2014, 130, e110-2.	1.6	5
189	Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE. <i>International Journal of Cardiology</i> , 2020, 317, 188-192.	0.8	5
190	Application of the REVEAL risk score calculator 2.0 in the PATENT study. <i>International Journal of Cardiology</i> , 2021, 332, 189-192.	0.8	5
191	Impact of Pulmonary Arterial Hypertension on Employment, Work Productivity, and Quality of Life - Results of a Cross-Sectional Multi-Center Study. <i>Frontiers in Psychiatry</i> , 2021, 12, 781532.	1.3	5
192	Enoximone in status asthmaticus. <i>ERJ Open Research</i> , 2020, 6, 00367-2019.	1.1	4
193	Change in REVEAL Lite 2 risk score predicts outcomes in patients with pulmonary arterial hypertension in the PATENT study. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 411-420.	0.3	4
194	Is sitaxsentan a safe and efficacious treatment for pulmonary arterial hypertension?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, 536-537.	3.3	3
195	Pulmonary vascular indices and survival in left heart disease: illusion of conclusion?. <i>European Journal of Heart Failure</i> , 2018, 20, 256-259.	2.9	3
196	Chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: to screen or not to screen?. <i>European Respiratory Journal</i> , 2018, 51, 1800440.	3.1	3
197	Pulmonary Artery Denervation. <i>Journal of the American College of Cardiology</i> , 2020, 76, 927-929.	1.2	3
198	Pulmonary hypertension in fibrosing idiopathic interstitial pneumonia: Uncertainties, challenges and opportunities. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 872-881.	0.3	3

#	ARTICLE	IF	CITATIONS
199	Health Disparities and Differences in Health-Care-Utilization in Patients With Pulmonary Arterial Hypertension. <i>Frontiers in Psychiatry</i> , 2022, 13, 813506.	1.3	3
200	The answer is blowing in the wind: an uncommon cause for severe ARDS accompanied by circulatory insufficiency requiring extracorporeal membrane oxygenation. <i>BMJ Case Reports</i> , 2017, 2017, bcr2016218079.	0.2	2
201	Maintenance Immunosuppression Is Associated With Better Outcome in the 2017/2018 Influenza Epidemic. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz381.	0.4	2
202	Motion Reduction for C-Arm Computed Tomography of the Pulmonary Arteries: Image Quality of a Motion Correction Algorithm in Patients with Chronic Thromboembolic Hypertension During Balloon Pulmonary Angioplasty. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2021, 193, 1074-1080.	0.7	2
203	Pregnancy in PAH: Reality is changing. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 395-396.	0.3	2
204	Liver-first strategy for a combined lung and liver transplant in patients with cystic fibrosis. <i>European Journal of Cardio-thoracic Surgery</i> , 2021, 60, 822-830.	0.6	2
205	Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension. <i>BMC Pulmonary Medicine</i> , 2021, 21, 164.	0.8	2
206	Splenectomy-Induced Portal Hypertension and Pulmonary Hypertension. <i>Annals of Internal Medicine</i> , 1999, 131, 793.	2.0	2
207	Metacognitions in Patients With Frequent Mental Disorders After Diagnosis of Pulmonary Arterial Hypertension. <i>Frontiers in Psychiatry</i> , 2022, 13, 812812.	1.3	2
208	Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?. <i>Genes</i> , 2022, 13, 759.	1.0	2
209	Sitaxentan in Pulmonary Arterial Hypertension. <i>Drugs</i> , 2007, 67, 771-772.	4.9	1
210	Predicting recurrent pulmonary embolism and chronic thromboembolic pulmonary hypertension: one more way to skin the cat. <i>European Respiratory Journal</i> , 2017, 49, 1700413.	3.1	1
211	Extracorporeal portosystemic shunt in secondary Budd-Chiari syndrome. <i>Journal of Hepatology</i> , 2020, 73, 974-976.	1.8	1
212	Subtle signs – red flags. <i>European Respiratory Journal</i> , 2020, 55, 2000606.	3.1	1
213	Advances in Prostanoid Therapy: New Studies, New Methods of Delivery. <i>Advances in Pulmonary Hypertension</i> , 2006, 5, 23-30.	0.1	1
214	Childhood Maltreatment, Mental Well-Being, and Healthy Lifestyle in Patients With Chronic Thromboembolic Pulmonary Hypertension. <i>Frontiers in Psychiatry</i> , 2022, 13, 821468.	1.3	1
215	Metacognitive Short-Term Intervention in Patients With Mental Disorders Following Cardiovascular Events. <i>Frontiers in Psychiatry</i> , 2022, 13, 812807.	1.3	1
216	Application of the REVEAL risk score calculator 2.0 in the CHEST study. <i>Respiratory Medicine</i> , 2022, 195, 106783.	1.3	1

#	ARTICLE	IF	CITATIONS
217	Recurrent Life-threatening Pneumonitis in a 37-Year-Old Woman. <i>Chest</i> , 2020, 158, e127-e132.	0.4	0
218	Response to Badagliacca etÂal: Multi-dimensional assessment and cluster analysis for idiopathic pulmonary arterial hypertension phenotyping. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 167-168.	0.3	0
219	High Incidence of Epileptiform Potentials During Continuous EEG Monitoring in Critically Ill COVID-19 Patients. <i>Frontiers in Medicine</i> , 2021, 8, 613951.	1.2	0
220	Depiction of mosaic perfusion in chronic thromboembolic pulmonary hypertension (CTEPH) on C-arm computed tomography compared to computed tomography pulmonary angiogram (CTPA). <i>Scientific Reports</i> , 2021, 11, 20042.	1.6	0
221	Virus-Associated Hemophagocytic Syndrome Contributes to Fatal Outcome In Critical Ill Patients with 2009 Influenza A (H1N1) Infection.. <i>Blood</i> , 2010, 116, 3795-3795.	0.6	0
222	Gas exchange: the neglected piece in the PAH puzzle. <i>European Respiratory Journal</i> , 2021, 58, 2101407.	3.1	0
223	Childhood Trauma in Patients With PAHâ€Prevalence, Impact on QoL, and Mental Healthâ€A Preliminary Report. <i>Frontiers in Psychiatry</i> , 2022, 13, 812862.	1.3	0
224	Combination Therapy for Pulmonary Arterial Hypertension. , 0, , 127-145.		0
225	Lung transplantation and severe coronary artery disease: results from a single-centre experience. <i>European Journal of Cardio-thoracic Surgery</i> , 0, , .	0.6	0